Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare disease targets.

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...

DelveInsight's severe asthma pipeline report depicts a robust space ... Teva Branded Pharmaceutical Industries, Sanofi, Jiangsu Hengrui Medicine, AstraZeneca, Advagene Biopharma, Genrix (Shanghai ...

Sanofi is currently conducting a phase II study on this candidate. Denali also has multiple early-stage clinical and preclinical programs in its pipeline. The FDA has selected its experimental ...

Sanofi, Jiangsu Hengrui Medicine, AstraZeneca, Advagene Biopharma, Genrix (Shanghai) Biopharmaceuticals, and others are evaluating new severe asthma drugs to improve the treatment landscape. Promising ...

However, VIR also pivoted to oncology, discontinuing vaccines and viral immunotherapy, and partnered with Sanofi to leverage ... applications and refresh its pipeline. Nevertheless, I also ...

Collaboration revenues in the third quarter were mostly earned due to the company’s association with bigwig Sanofi SNY. Shares of KYMR have surged 81.3% year to date against the industry’s ...